We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Redhill BioPharma Nabs Mexican Approval for Phase 2/3 Trial of Yeliva for COVID-19
Redhill BioPharma Nabs Mexican Approval for Phase 2/3 Trial of Yeliva for COVID-19
Mexico’s drug regulators have approved RedHill Biopharma’s planned phase 2/3 trial of Yeliva (opaganib) in hospitalized COVID-19 patients with pneumonia.